{"id":531496,"date":"2021-02-24T06:50:01","date_gmt":"2021-02-24T06:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531496"},"modified":"2021-02-24T06:50:01","modified_gmt":"2021-02-24T06:50:01","slug":"persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2030-by-delveinsight_531496.html","title":{"rendered":"Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2030 by DelveInsight"},"content":{"rendered":"
\"Persistent<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Persistent Epithelial Defect (PED) – Market Insights, Epidemiology, and Market Forecast – 2030\u2019 report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Persistent Epithelial Defect (PED) Market Insights, Epidemiology, and Market Forecast 2030<\/strong><\/a>.<\/p>\n

DelveInsight’s ‘Persistent Epithelial Defect (PED) Market Report 2030<\/a><\/strong>’ report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Persistent Epithelial Disease Overview:<\/strong><\/p>\n

Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10–14 days after a corneal injury, even with standard supportive treatment. PED is defined as “defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses”. PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7–14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.<\/p>\n

Persistent Epithelial Disease Epidemiology insights:<\/strong><\/p>\n

The total Incident population of Persistent Epithelial Defect (PED) in 7MM countries was estimated to be 238,058 cases in 2017.<\/span><\/p>\n

Persistent Epithelial Disease Emerging therapies:<\/strong><\/p>\n

1. Nexagon by OcuNexus Therapeutics, Eyevance Pharmaceuticals<\/span><\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-market<\/span><\/a><\/strong><\/p>\n

Persistent Epithelial Disease Market Outlook<\/strong><\/p>\n

The Persistent Epithelial Defect (PED) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Persistent Epithelial Defect (PED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.<\/p>\n

The first step in the management of any epithelial abnormality is to determine the etiology of the disease. Currently, “bandage” methods are used to help re-epithelialize a cornea. The current approaches include Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Tetracyclines, prophylactic topical antibiotics and steroids. For the treatment of refractory cases, Amniotic membrane grafting, autologous serum, Scleral contact lenses, and others have recommended. In severe cases, a conjunctival graft may be placed over the cornea. <\/p>\n

This section includes a glimpse of the Persistent Epithelial Defect market<\/strong><\/a> in 7MM. The market size of PED in the seven major markets was found to be USD 179.1 million in 2017.<\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insight
2 Executive Summary of Persistent Epithelial Defect (PED)
3 Persistent Epithelial Defect (PED) Market Overview at a Glance
4 Disease Background and Overview: Persistent Epithelial Defect (PED)
5 Case Reports
6 Persistent Epithelial Defect (PED) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Persistent Epithelial Defect (PED) Treatment and Medical Practices
11 Unmet needs
12 Persistent Epithelial Defect (PED) Marketed Drugs
13 Persistent Epithelial Defect (PED) Emerging Drugs
14 Persistent Epithelial Defect (PED) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Persistent Epithelial Defect (PED) Market Drivers
19 Persistent Epithelial Defect (PED) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

Download report: https:\/\/www.delveinsight.com\/report-store\/persistent-corneal-epithelial-defects-market<\/span><\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Persistent Epithelial Defect (PED) – Market Insights, Epidemiology, and Market Forecast – 2030\u2019 report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531496","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531496"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}